<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01618669</url>
  </required_header>
  <id_info>
    <org_study_id>3606-CL-3004</org_study_id>
    <nct_id>NCT01618669</nct_id>
  </id_info>
  <brief_title>A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)</brief_title>
  <acronym>EXERRT</acronym>
  <official_title>A Phase 3b, Open-Label, Parallel Group, Randomized, Multicenter Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Global Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that the strength of agreement between single
      photon emission computed tomography (SPECT) imaging with regadenoson following inadequate
      exercise stress testing and SPECT imaging with regadenoson alone is not inferior to the
      strength of agreement between two sequential regadenoson SPECT images without exercise.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants With Majority Reader Self-agreement in Ischemia Assessment Between First and Second Stress Scans</measure>
    <time_frame>Day 1 (rest scan and first stress scan) and Day 2 -15 (second stress scan)</time_frame>
    <description>SPECT scans were reviewed in a blinded fashion by 3 independent expert readers using the 17-segment model for standardized myocardial segmentation. At rest and stress, each segment was scored on a 0 (normal) to 4 (absent contrast/radiotracer uptake) scale by each of the 3 blinded readers according to the amount of contrast or radiotracer the myocardium in the segment absorbed. If the stress score was ≥ 2 and the rest score was less than the stress score, the segment was counted as having a reversible defect.
The number of segments with reversible defects was categorized as absence (0 - 1 reversible segments) or presence (≥ 2 defects reversible segments) of ischemia.
Each reader was defined as having self-agreement based upon identical categorization of a given participant as absent or present for ischemia for both the initial and second stress visits.
Majority agreement is if at least 2 out of the 3 blinded readers demonstrated self-agreement for a given participant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events</measure>
    <time_frame>Within 1 hour for ECG events and up to 24 hours for adverse events after administration of regadenoson</time_frame>
    <description>A clinically significant cardiac event is defined as:
Any of the following events found on the Holter electrocardiogram (ECG)/12-Lead ECG within 1 hour after regadenoson administration:
ventricular arrhythmias (sustained ventricular tachycardia, ventricular fibrillation, torsade de pointes, ventricular flutter),
ST-T depression (&gt; 2 mm),
ST-T elevation (≥1 mm),
Atrioventricular (AV) block (2:1 AV block, AV Mobitz I, AV Mobitz II, complete heart block)
sinus arrest &gt; 3 seconds in duration
Or
a treatment-emergent adverse event (TEAE) per the Medical Dictionary for Regulatory Activities (MedDRA) Standardised MedDRA Queries (SMQ) (Narrow Scope) for myocardial infarction
Or
a TEAE preferred term of angina unstable within 24 hours of regadenoson administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Agreement in the Assessment of Absence or Presence of Ischemia Between First and Second Stress Scans</measure>
    <time_frame>Day 1 (stress MPI 1) and Day 2 -15 (stress MPI 2)</time_frame>
    <description>The number of segments with reversible defects was assessed by each of the 3 blinded independent expert readers. Based on the median count of the number of reversible defects across the 3 readers, categorized as absence (0 to 1 reversible segments) or presence (≥ 2 reversible defects) of ischemia, the proportion of participants with agreement in the presence and absence of ischemia between the first and second stress scans was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Agreement in the Assessment of Reversible Defects in 3 Categories of Ischemia Between First and Second Stress Scans</measure>
    <time_frame>Day 1 (stress MPI 1) and Day 2 - 15 (stress MPI 2)</time_frame>
    <description>The number of segments with reversible defects was assessed by each of the 3 blinded independent expert readers. Based on the median count of the number of reversible defects across the 3 readers, categorized as 0 to 1, 2 to 4, or ≥ 5 reversible segments, the proportion of participants with agreement in the three ischemia categories between the first and second stress scans was to be calculated. In the reported data, these proportions only include the 0-1 and 2-4 categories; the ≥ 5 category was not included because there were no participants in this category for the Regadenoson Alone group for the initial stress MPI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Agreement in the Summed Stress Score (SSS) Between First and Second Stress Scans</measure>
    <time_frame>Day 1 (stress MPI 1) and Day 2 - 15 (stress MPI 2)</time_frame>
    <description>The 17-segment model for standardized myocardial segmentation was used to analyze MPI scans. Each segment was scored on a 0 to 4 scale according to the amount of contrast or radiotracer the myocardium in the segment absorbed:
0: normal perfusion
1: slightly reduced contrast/radiotracer uptake
2: moderately reduced contrast/radiotracer uptake
3: severely reduced contrast/radiotracer uptake
4: absent contrast/radiotracer uptake.
The Summed Stress Score (SSS) was calculated as the sum of the stress scores across the 17 segments. The mean value (rounded to the nearest integer) across the 3 readers was computed and the SSS was categorized into 4 group categorical variables based on the score: 0 to 3, 4 to 7, 8 to 11, and ≥ 12. The proportion of participants with agreement in respect to these categories between the two stress scans was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Agreement in the Summed Difference Score (SDS) Between First and Second Stress Scans</measure>
    <time_frame>Day 1 (rest MPI and stress MPI 1) and Day 2 - 15 (stress MPI 2)</time_frame>
    <description>The 17-segment model for standardized myocardial segmentation was used to analyze MPI scans. At rest and stress, each segment was scored on a 0 to 4 scale according to the amount of contrast or radiotracer the myocardium in the segment absorbed:
0: normal perfusion
1: slightly reduced contrast/ uptake
2: moderately reduced contrast/uptake
3: severely reduced contrast/uptake
4: absent contrast/uptake.
SSS was calculated as the sum of the stress scores across the 17 segments and the Summed Rest Score (SRS) was calculated as the sum of the rest scores across the 17 segments. The Summed Difference Score (SDS) is the difference in the SSS and SRS (SSS - SRS).
The mean value (rounded to the nearest integer) across the 3 readers was computed and the SDS was categorized into 3 categorical variables based on the score: 0 to 6, 7 to 13 and ≥ 14. The proportion of participants with agreement in respect to these categories between the two stress scans was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Less, the Same, or More Reversible Perfusion Defects Shown by the First Stress Scan When Compared to the Second Stress Scan</measure>
    <time_frame>Day 1 (stress MPI 1) and Day 2-15 (stress MPI 2)</time_frame>
    <description>Each reader evaluated the initial stress SPECT MPI scan compared to the participant's second stress SPECT MPI scan (blinded at time of the evaluation) for whether there was Less (-1), the Same (0) or More (1) reversible perfusion defects. The median assessment of the 3 blinded readers was used to summarize the number of participants in each category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Assessment of Image Quality</measure>
    <time_frame>Day 1 (rest MPI and stress MPI 1) and Day 2 - 15 (stress MPI 2)</time_frame>
    <description>The image quality for each scan was rated by each independent reader as 1 = Poor, 2 = Fair, 3 = Good, 4 = Excellent. Based on the median rating of overall image quality across the three readers, the number of participants with each rating is reported for each scan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target to Background Radiotracer Uptake Ratios From the First and Second Stress Scans</measure>
    <time_frame>Day 1 (stress MPI 1) and Day 2 - 15 (stress MPI 2)</time_frame>
    <description>Image quality was assessed through radiotracer uptake in the heart (target organ) compared to liver, gut and combined liver plus gut (background interference).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Scans With Subdiaphragmatic Interference</measure>
    <time_frame>Day 1 (stress MPI 1) and Day 2 -15 (stress MPI 2)</time_frame>
    <description>Each reader assessed the sub-diaphragmatic radiotracer interference with cardiac image quality using a 4-point scale of 0 = none, 1 = slight, 2 = moderate or 3 = severe for each stress SPECT MPI. The median rating across the 3 readers was used to summarize the percentage of scans with interference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity</measure>
    <time_frame>Day 1 (stress MPI 1) and Day - 15 (stress MPI 2)</time_frame>
    <description>The number of cardiac segments obscured by the sub-diaphragmatic activity by group by stress SPECT MPI scan and by reader is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events Within 24 Hours After Administration of Regadenoson</measure>
    <time_frame>Up to 24 hours after study drug administration for each stress MPI (Day 1 and Day 2-15)</time_frame>
    <description>An adverse event is considered &quot;serious&quot; if, in the view of either the investigator or sponsor, it results in any of the following outcomes:
Results in death,
Is life threatening,
Results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions,
Results in congenital anomaly, or birth defect,
Requires inpatient hospitalization or leads to prolongation of hospitalization
Other medically important events.
Relationship to study drug was assessed by the investigator.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1147</enrollment>
  <condition>Coronary Artery Disease (CAD)</condition>
  <arm_group>
    <arm_group_label>Regadenoson After Peak Exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regadenoson Alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus (1 hour after exercise recovery), and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regadenoson</intervention_name>
    <description>Administered as an intravenous (IV) bolus</description>
    <arm_group_label>Regadenoson After Peak Exercise</arm_group_label>
    <arm_group_label>Regadenoson Alone</arm_group_label>
    <other_name>Lexiscan</other_name>
    <other_name>CVT3146</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)</intervention_name>
    <arm_group_label>Regadenoson After Peak Exercise</arm_group_label>
    <arm_group_label>Regadenoson Alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects referred for an exercise or pharmacologic stress test SPECT MPI procedure for
             the evaluation of coronary artery disease (CAD) are eligible for study participation.
             Subjects referred for pharmacologic stress should have a reasonable potential of
             attempting exercise stress. Subject must have one of the following:

               -  a. Past ischemia on any prior imaging stress test without invasive intervention
                  on the artery subtending this territory

               -  b. Subject with known CAD who have symptoms similar to previous ischemic
                  symptoms, or recent onset of symptoms or recently worsened symptoms suggestive of
                  ischemia

               -  c. Diamond Forrester estimated pretest probability of CAD of ≥ 50%

               -  d. History of most recent coronary artery bypass surgery or most recent
                  percutaneous coronary intervention (PCI) &gt; 10 years (patients who are &gt; 30 days
                  but less than 10 years post coronary artery bypass graft (CABG) or PCI can be
                  included if they meet criteria a, b, or e)

               -  e. Previously demonstrated 100% occlusion by invasive coronary or computed
                  tomography (CT) angiography without successful intervening revascularization as
                  these foods may alter regadenoson effects

        Exclusion Criteria:

          -  Subject has a clinically significant illness, medical condition, or laboratory
             abnormality

          -  Female subject who is pregnant or lactating

          -  Subject is on dialysis for end stage renal disease or has a history of glomerular
             filtration rate (GFR) &lt; 15 mL/min (calculated using MDRD [Modification of Diet in
             Renal Disease] formula)

          -  Subject has a history of coronary revascularization by either PCI or CABG within 1
             month prior to the rest myocardial perfusion imaging (MPI)

          -  Subject has a pacemaker or an implantable cardioverter defibrillator (ICD)

          -  Subject has a history of acute myocardial infarction (MI) or high risk unstable angina
             within 30 days prior to the rest MPI or has had cardiac transplantation

          -  Subject has uncontrolled hypertension at any point on Visit 2 prior to exercise
             testing (i.e., systolic blood pressure (SBP) ≥ 180 or diastolic blood pressure (DBP) ≥
             95 mmHg on two consecutive measurements while at rest).

          -  Subject has severe aortic stenosis or hypertrophic cardiomyopathy with obstruction or
             has decompensated congestive heart failure

          -  Subject has a history of severe respiratory disease including: asthma, chronic
             obstructive pulmonary disease (COPD) or other bronchospastic reactive airway disease
             or who is on 24-hour continuous oxygen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Senior Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mobile Heart Specialists, PC</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silicon Valley Medical Imaging</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Beach Memorial Medical Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Greater Los Angeles Healthcare System</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westside Medical Associates of Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ventura Clinical Trials</name>
      <address>
        <city>Malibu</city>
        <state>California</state>
        <zip>90265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Internal Medical Group</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA San Diego Healthcare System</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Rosa Cardiology Medical Group, Inc.</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Los Angeles Biomedical Research Institute</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOCC - New Britain Campus</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <zip>06050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfieri Cardiology</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delaware Clinical Trials</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elite Research and Clinical Trials</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S &amp; W Clinical Research</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Heart Associates</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Coast Institute for Research, LLC</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Cardiology St. Vincent's HealthCare</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Medical Clinic/Lakeland Regional Medical Clinic</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MIMA Century Research Associates</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Research Center of South Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital/Cardiovascular Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Partners Clinical Research Institute</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Cardiology Associates, LLC</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Coast Medical Group</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I U School of Medicine/ Krannert Institute of Cardiology</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Cardiology Associates</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Research Associates</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berkshire Medical Center</name>
      <address>
        <city>Pittsfield</city>
        <state>Massachusetts</state>
        <zip>01201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detriot</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Heart</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Associates of North Mississippi</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Imaging Technologies</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alegent Health Heart and Vascular Specialists</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alegent Health Research Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Las Vegas Radiology</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laurelton Medical center</name>
      <address>
        <city>Laurelton</city>
        <state>New York</state>
        <zip>11422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westchester Medical Center-New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buffalo Cardiology &amp; Pulmonary Associates, P.C.</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berks Cardiologists, Ltd.</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katy Cardiology Associates</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77493</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Research Institute LLC</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Houston Area Clinical Trial Consultants, LLC</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roanoke Heart Institute, PC</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano Garibaldi</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fé</state>
        <zip>S2000ODA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Oulton</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000JJS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Cardiologia la Plata</name>
      <address>
        <city>La Plata</city>
        <zip>B1925XAC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de La Plata</name>
      <address>
        <city>Provincia de Buenos Aires</city>
        <zip>B1900AX</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio San Geronimo</name>
      <address>
        <city>Santa Fe</city>
        <zip>S3001XAF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Anglo Americana</name>
      <address>
        <city>Lima</city>
        <zip>Lima 27</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arzobispo Loayza</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional Cardiovascular de EsSalud</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Caribbean Healthcare System (672)</name>
      <address>
        <city>San Juan</city>
        <zip>00921</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Peru</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.astellasclinicalstudyresults.com/study.aspx?ID=3606-CL-3004</url>
    <description>Link to results on Astellas Clinical Study Results Web site</description>
  </link>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2012</study_first_submitted>
  <study_first_submitted_qc>June 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2012</study_first_posted>
  <results_first_submitted>December 14, 2015</results_first_submitted>
  <results_first_submitted_qc>January 7, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 8, 2016</results_first_posted>
  <last_update_submitted>January 7, 2016</last_update_submitted>
  <last_update_submitted_qc>January 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Artery Disease (CAD)</keyword>
  <keyword>regadenoson</keyword>
  <keyword>pharmacologic stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Regadenoson</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 49 sites in a total of 3 countries including the United States (44 sites), Argentina (4 sites) and Peru (1 site).</recruitment_details>
      <pre_assignment_details>At Baseline, patients meeting all inclusion/exclusion criteria completed single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) while at rest. Participants then underwent a Bruce or modified Bruce exercise protocol; those unable to reach 85% maximum predicted heart rate and/or 5 metabolic equivalents were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Regadenoson After Peak Exercise</title>
          <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT myocardial perfusion imaging (MPI). One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
        </group>
        <group group_id="P2">
          <title>Regadenoson Alone</title>
          <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="578"/>
                <participants group_id="P2" count="569"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="575"/>
                <participants group_id="P2" count="567"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="544"/>
                <participants group_id="P2" count="546"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but Never Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous Reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants who took at least 1 dose of study drug (Safety Analysis Set).</population>
      <group_list>
        <group group_id="B1">
          <title>Regadenoson After Peak Exercise</title>
          <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
        </group>
        <group group_id="B2">
          <title>Regadenoson Alone</title>
          <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="575"/>
            <count group_id="B2" value="567"/>
            <count group_id="B3" value="1142"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.9" spread="11.45"/>
                    <measurement group_id="B2" value="61.9" spread="11.19"/>
                    <measurement group_id="B3" value="61.9" spread="11.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="234"/>
                    <measurement group_id="B2" value="239"/>
                    <measurement group_id="B3" value="473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="341"/>
                    <measurement group_id="B2" value="328"/>
                    <measurement group_id="B3" value="669"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bruce Exercise Group</title>
          <description>The Bruce exercise test involves walking on a treadmill while the heart is monitored by an electrocardiograph. The protocol consists of several stages of progressively greater workloads.
The Modified Bruce protocol starts at a lower workload than the standard test and is typically used for elderly or sedentary patients.
Data are reported for all randomized participants with interpretable SPECT scans at all visits as determined by at least 2 of the 3 blinded independent expert readers (full analysis set; 538 and 534 participants in each treatment group respectively).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Standard Bruce Exercise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="448"/>
                    <measurement group_id="B2" value="442"/>
                    <measurement group_id="B3" value="890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Modified Bruce Exercise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Maximum Metabolic Equivalents Achieved</title>
          <description>A metabolic unit used to quantify the intensity of physical activity, which is defined as the ratio of the metabolic rate during exercise to the metabolic rate at rest. One MET corresponds to an energy expenditure of approximately 1 kcal/kg/hour, or an oxygen uptake of 3.5 ml of O2 consumption/kg/hour.
Data are provided for the full analysis set (538 and 534 participants in each treatment group respectively).</description>
          <units>metabolic equivalents</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.45" spread="2.284"/>
                    <measurement group_id="B2" value="5.37" spread="2.331"/>
                    <measurement group_id="B3" value="5.41" spread="2.307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Participants With Majority Reader Self-agreement in Ischemia Assessment Between First and Second Stress Scans</title>
        <description>SPECT scans were reviewed in a blinded fashion by 3 independent expert readers using the 17-segment model for standardized myocardial segmentation. At rest and stress, each segment was scored on a 0 (normal) to 4 (absent contrast/radiotracer uptake) scale by each of the 3 blinded readers according to the amount of contrast or radiotracer the myocardium in the segment absorbed. If the stress score was ≥ 2 and the rest score was less than the stress score, the segment was counted as having a reversible defect.
The number of segments with reversible defects was categorized as absence (0 - 1 reversible segments) or presence (≥ 2 defects reversible segments) of ischemia.
Each reader was defined as having self-agreement based upon identical categorization of a given participant as absent or present for ischemia for both the initial and second stress visits.
Majority agreement is if at least 2 out of the 3 blinded readers demonstrated self-agreement for a given participant.</description>
        <time_frame>Day 1 (rest scan and first stress scan) and Day 2 -15 (second stress scan)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Regadenoson After Peak Exercise</title>
            <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
          </group>
          <group group_id="O2">
            <title>Regadenoson Alone</title>
            <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With Majority Reader Self-agreement in Ischemia Assessment Between First and Second Stress Scans</title>
          <description>SPECT scans were reviewed in a blinded fashion by 3 independent expert readers using the 17-segment model for standardized myocardial segmentation. At rest and stress, each segment was scored on a 0 (normal) to 4 (absent contrast/radiotracer uptake) scale by each of the 3 blinded readers according to the amount of contrast or radiotracer the myocardium in the segment absorbed. If the stress score was ≥ 2 and the rest score was less than the stress score, the segment was counted as having a reversible defect.
The number of segments with reversible defects was categorized as absence (0 - 1 reversible segments) or presence (≥ 2 defects reversible segments) of ischemia.
Each reader was defined as having self-agreement based upon identical categorization of a given participant as absent or present for ischemia for both the initial and second stress visits.
Majority agreement is if at least 2 out of the 3 blinded readers demonstrated self-agreement for a given participant.</description>
          <population>Full Analysis Set</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="538"/>
                <count group_id="O2" value="535"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" lower_limit="0.89" upper_limit="0.94"/>
                    <measurement group_id="O2" value="0.95" lower_limit="0.93" upper_limit="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the lower confidence bound of the 1-sided alpha level of 0.025 of the difference in the proportion of participants with majority reader self-agreement exceeded -0.075, non-inferiority would be demonstrated.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.015</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.06</ci_lower_limit>
            <ci_upper_limit>-0.00</ci_upper_limit>
            <estimate_desc>Difference equals Regadenoson After Peak Exercise minus Regadenoson Alone</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events</title>
        <description>A clinically significant cardiac event is defined as:
Any of the following events found on the Holter electrocardiogram (ECG)/12-Lead ECG within 1 hour after regadenoson administration:
ventricular arrhythmias (sustained ventricular tachycardia, ventricular fibrillation, torsade de pointes, ventricular flutter),
ST-T depression (&gt; 2 mm),
ST-T elevation (≥1 mm),
Atrioventricular (AV) block (2:1 AV block, AV Mobitz I, AV Mobitz II, complete heart block)
sinus arrest &gt; 3 seconds in duration
Or
a treatment-emergent adverse event (TEAE) per the Medical Dictionary for Regulatory Activities (MedDRA) Standardised MedDRA Queries (SMQ) (Narrow Scope) for myocardial infarction
Or
a TEAE preferred term of angina unstable within 24 hours of regadenoson administration.</description>
        <time_frame>Within 1 hour for ECG events and up to 24 hours for adverse events after administration of regadenoson</time_frame>
        <population>Safety analysis set (all randomized participants who received at least 1 dose of regadenoson study drug)</population>
        <group_list>
          <group group_id="O1">
            <title>Regadenoson After Peak Exercise: MPI 1</title>
            <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
          </group>
          <group group_id="O2">
            <title>Regadenoson After Peak Exercise: MPI 2</title>
            <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
          </group>
          <group group_id="O3">
            <title>Regadenoson Alone: MPI 1</title>
            <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
          </group>
          <group group_id="O4">
            <title>Regadenoson Alone: MPI 2</title>
            <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events</title>
          <description>A clinically significant cardiac event is defined as:
Any of the following events found on the Holter electrocardiogram (ECG)/12-Lead ECG within 1 hour after regadenoson administration:
ventricular arrhythmias (sustained ventricular tachycardia, ventricular fibrillation, torsade de pointes, ventricular flutter),
ST-T depression (&gt; 2 mm),
ST-T elevation (≥1 mm),
Atrioventricular (AV) block (2:1 AV block, AV Mobitz I, AV Mobitz II, complete heart block)
sinus arrest &gt; 3 seconds in duration
Or
a treatment-emergent adverse event (TEAE) per the Medical Dictionary for Regulatory Activities (MedDRA) Standardised MedDRA Queries (SMQ) (Narrow Scope) for myocardial infarction
Or
a TEAE preferred term of angina unstable within 24 hours of regadenoson administration.</description>
          <population>Safety analysis set (all randomized participants who received at least 1 dose of regadenoson study drug)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="575"/>
                <count group_id="O2" value="544"/>
                <count group_id="O3" value="567"/>
                <count group_id="O4" value="548"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="0.9"/>
                    <measurement group_id="O3" value="0.5"/>
                    <measurement group_id="O4" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Holter/12-Lead ECG Abnormality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8"/>
                    <measurement group_id="O2" value="0.9"/>
                    <measurement group_id="O3" value="0.5"/>
                    <measurement group_id="O4" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sustained Ventricular Tachycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ventricular Fibrillation or Ventricular Flutter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Torsade de Pointes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ST-T Depression (≥ 2 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                    <measurement group_id="O2" value="0.6"/>
                    <measurement group_id="O3" value="0.4"/>
                    <measurement group_id="O4" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ST-T Elevation (≥ 1 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.4"/>
                    <measurement group_id="O3" value="0.2"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2:1 AV Block</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mobitz I Second Degree AV Block</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mobitz II Second Degree AV Block</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Heart Block</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pause &gt; 3.0 seconds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE per SMQ for Myocardial Infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute Coronary Syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myocardial Infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse Event of Angina Unstable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With Agreement in the Assessment of Absence or Presence of Ischemia Between First and Second Stress Scans</title>
        <description>The number of segments with reversible defects was assessed by each of the 3 blinded independent expert readers. Based on the median count of the number of reversible defects across the 3 readers, categorized as absence (0 to 1 reversible segments) or presence (≥ 2 reversible defects) of ischemia, the proportion of participants with agreement in the presence and absence of ischemia between the first and second stress scans was calculated.</description>
        <time_frame>Day 1 (stress MPI 1) and Day 2 -15 (stress MPI 2)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Regadenoson After Peak Exercise</title>
            <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
          </group>
          <group group_id="O2">
            <title>Regadenoson Alone</title>
            <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With Agreement in the Assessment of Absence or Presence of Ischemia Between First and Second Stress Scans</title>
          <description>The number of segments with reversible defects was assessed by each of the 3 blinded independent expert readers. Based on the median count of the number of reversible defects across the 3 readers, categorized as absence (0 to 1 reversible segments) or presence (≥ 2 reversible defects) of ischemia, the proportion of participants with agreement in the presence and absence of ischemia between the first and second stress scans was calculated.</description>
          <population>Full Analysis Set</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="538"/>
                <count group_id="O2" value="535"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" lower_limit="0.68" upper_limit="0.83"/>
                    <measurement group_id="O2" value="0.77" lower_limit="0.67" upper_limit="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The lower confidence bound of the 1-sided alpha level of 0.025 of the difference in agreement rates must exceed -0.10 in order to demonstrate non-inferiority.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.063</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.14</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
            <estimate_desc>Difference equals Regadenoson After Peak Exercise minus Regadenoson Alone</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With Agreement in the Assessment of Reversible Defects in 3 Categories of Ischemia Between First and Second Stress Scans</title>
        <description>The number of segments with reversible defects was assessed by each of the 3 blinded independent expert readers. Based on the median count of the number of reversible defects across the 3 readers, categorized as 0 to 1, 2 to 4, or ≥ 5 reversible segments, the proportion of participants with agreement in the three ischemia categories between the first and second stress scans was to be calculated. In the reported data, these proportions only include the 0-1 and 2-4 categories; the ≥ 5 category was not included because there were no participants in this category for the Regadenoson Alone group for the initial stress MPI.</description>
        <time_frame>Day 1 (stress MPI 1) and Day 2 - 15 (stress MPI 2)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Regadenoson After Peak Exercise</title>
            <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
          </group>
          <group group_id="O2">
            <title>Regadenoson Alone</title>
            <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With Agreement in the Assessment of Reversible Defects in 3 Categories of Ischemia Between First and Second Stress Scans</title>
          <description>The number of segments with reversible defects was assessed by each of the 3 blinded independent expert readers. Based on the median count of the number of reversible defects across the 3 readers, categorized as 0 to 1, 2 to 4, or ≥ 5 reversible segments, the proportion of participants with agreement in the three ischemia categories between the first and second stress scans was to be calculated. In the reported data, these proportions only include the 0-1 and 2-4 categories; the ≥ 5 category was not included because there were no participants in this category for the Regadenoson Alone group for the initial stress MPI.</description>
          <population>Full Analysis Set</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="538"/>
                <count group_id="O2" value="535"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" lower_limit="0.69" upper_limit="0.77"/>
                    <measurement group_id="O2" value="0.75" lower_limit="0.71" upper_limit="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The lower confidence bound of the 1-sided alpha level of 0.025 of the difference in agreement rates must exceed -0.133 in order to demonstrate non-inferiority. Non-inferiority could not be assessed because of insufficient data in the Regadenoson Alone group.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.07</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With Agreement in the Summed Stress Score (SSS) Between First and Second Stress Scans</title>
        <description>The 17-segment model for standardized myocardial segmentation was used to analyze MPI scans. Each segment was scored on a 0 to 4 scale according to the amount of contrast or radiotracer the myocardium in the segment absorbed:
0: normal perfusion
1: slightly reduced contrast/radiotracer uptake
2: moderately reduced contrast/radiotracer uptake
3: severely reduced contrast/radiotracer uptake
4: absent contrast/radiotracer uptake.
The Summed Stress Score (SSS) was calculated as the sum of the stress scores across the 17 segments. The mean value (rounded to the nearest integer) across the 3 readers was computed and the SSS was categorized into 4 group categorical variables based on the score: 0 to 3, 4 to 7, 8 to 11, and ≥ 12. The proportion of participants with agreement in respect to these categories between the two stress scans was calculated.</description>
        <time_frame>Day 1 (stress MPI 1) and Day 2 - 15 (stress MPI 2)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Regadenoson After Peak Exercise</title>
            <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
          </group>
          <group group_id="O2">
            <title>Regadenoson Alone</title>
            <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With Agreement in the Summed Stress Score (SSS) Between First and Second Stress Scans</title>
          <description>The 17-segment model for standardized myocardial segmentation was used to analyze MPI scans. Each segment was scored on a 0 to 4 scale according to the amount of contrast or radiotracer the myocardium in the segment absorbed:
0: normal perfusion
1: slightly reduced contrast/radiotracer uptake
2: moderately reduced contrast/radiotracer uptake
3: severely reduced contrast/radiotracer uptake
4: absent contrast/radiotracer uptake.
The Summed Stress Score (SSS) was calculated as the sum of the stress scores across the 17 segments. The mean value (rounded to the nearest integer) across the 3 readers was computed and the SSS was categorized into 4 group categorical variables based on the score: 0 to 3, 4 to 7, 8 to 11, and ≥ 12. The proportion of participants with agreement in respect to these categories between the two stress scans was calculated.</description>
          <population>Full Analysis Set</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="538"/>
                <count group_id="O2" value="535"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86"/>
                    <measurement group_id="O2" value="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.03</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With Agreement in the Summed Difference Score (SDS) Between First and Second Stress Scans</title>
        <description>The 17-segment model for standardized myocardial segmentation was used to analyze MPI scans. At rest and stress, each segment was scored on a 0 to 4 scale according to the amount of contrast or radiotracer the myocardium in the segment absorbed:
0: normal perfusion
1: slightly reduced contrast/ uptake
2: moderately reduced contrast/uptake
3: severely reduced contrast/uptake
4: absent contrast/uptake.
SSS was calculated as the sum of the stress scores across the 17 segments and the Summed Rest Score (SRS) was calculated as the sum of the rest scores across the 17 segments. The Summed Difference Score (SDS) is the difference in the SSS and SRS (SSS – SRS).
The mean value (rounded to the nearest integer) across the 3 readers was computed and the SDS was categorized into 3 categorical variables based on the score: 0 to 6, 7 to 13 and ≥ 14. The proportion of participants with agreement in respect to these categories between the two stress scans was calculated.</description>
        <time_frame>Day 1 (rest MPI and stress MPI 1) and Day 2 - 15 (stress MPI 2)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>REG APEX: MPI 2 SDS 0-6</title>
            <description>Participants in the Regadenoson After Peak Exercise (APEX) group who had an SDS from 0 to 6 on their second stress scan.</description>
          </group>
          <group group_id="O2">
            <title>REG APEX: MPI 2 7-13</title>
            <description>Participants in the Regadenoson After Peak Exercise (REG APEX) group who had an SDS from 7 to 13 on their second stress scan.</description>
          </group>
          <group group_id="O3">
            <title>REG APEX: MPI 2 SDS ≥ 14</title>
            <description>Participants in the Regadenoson After Peak Exercise (REG APEX) group who had an SDS ≥ 14 on their second stress scan.</description>
          </group>
          <group group_id="O4">
            <title>REG Alone: MPI 2 SDS 0-6</title>
            <description>Participants in the Regadenoson (REG) Alone group who had an SDS from 0 to 6 on their second stress scan.</description>
          </group>
          <group group_id="O5">
            <title>REG Alone: MPI 2 SDS 7-13</title>
            <description>Participants in the Regadenoson (REG) Alone group who had an SDS from 7 to 13 on their second stress scan.</description>
          </group>
          <group group_id="O6">
            <title>REG Alone: MPI 2 SDS ≥ 14</title>
            <description>Participants in the Regadenoson (REG) Alone group who had an SDS ≥ 14 on their second stress scan.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With Agreement in the Summed Difference Score (SDS) Between First and Second Stress Scans</title>
          <description>The 17-segment model for standardized myocardial segmentation was used to analyze MPI scans. At rest and stress, each segment was scored on a 0 to 4 scale according to the amount of contrast or radiotracer the myocardium in the segment absorbed:
0: normal perfusion
1: slightly reduced contrast/ uptake
2: moderately reduced contrast/uptake
3: severely reduced contrast/uptake
4: absent contrast/uptake.
SSS was calculated as the sum of the stress scores across the 17 segments and the Summed Rest Score (SRS) was calculated as the sum of the rest scores across the 17 segments. The Summed Difference Score (SDS) is the difference in the SSS and SRS (SSS – SRS).
The mean value (rounded to the nearest integer) across the 3 readers was computed and the SDS was categorized into 3 categorical variables based on the score: 0 to 6, 7 to 13 and ≥ 14. The proportion of participants with agreement in respect to these categories between the two stress scans was calculated.</description>
          <population>Full Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="538"/>
                <count group_id="O2" value="538"/>
                <count group_id="O3" value="538"/>
                <count group_id="O4" value="535"/>
                <count group_id="O5" value="535"/>
                <count group_id="O6" value="535"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPI 1 SDS 0-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="531"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="527"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPI 1 SDS 7-13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPI 1 SDS ≥ 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Less, the Same, or More Reversible Perfusion Defects Shown by the First Stress Scan When Compared to the Second Stress Scan</title>
        <description>Each reader evaluated the initial stress SPECT MPI scan compared to the participant's second stress SPECT MPI scan (blinded at time of the evaluation) for whether there was Less (-1), the Same (0) or More (1) reversible perfusion defects. The median assessment of the 3 blinded readers was used to summarize the number of participants in each category.</description>
        <time_frame>Day 1 (stress MPI 1) and Day 2-15 (stress MPI 2)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Regadenoson After Peak Exercise</title>
            <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
          </group>
          <group group_id="O2">
            <title>Regadenoson Alone</title>
            <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Less, the Same, or More Reversible Perfusion Defects Shown by the First Stress Scan When Compared to the Second Stress Scan</title>
          <description>Each reader evaluated the initial stress SPECT MPI scan compared to the participant's second stress SPECT MPI scan (blinded at time of the evaluation) for whether there was Less (-1), the Same (0) or More (1) reversible perfusion defects. The median assessment of the 3 blinded readers was used to summarize the number of participants in each category.</description>
          <population>Full Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="538"/>
                <count group_id="O2" value="535"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Less Reversible Perfusion Defects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Same Number of Reversible Perfusion Defects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="441"/>
                    <measurement group_id="O2" value="459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More Reversible Perfusion Defects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Assessment of Image Quality</title>
        <description>The image quality for each scan was rated by each independent reader as 1 = Poor, 2 = Fair, 3 = Good, 4 = Excellent. Based on the median rating of overall image quality across the three readers, the number of participants with each rating is reported for each scan.</description>
        <time_frame>Day 1 (rest MPI and stress MPI 1) and Day 2 - 15 (stress MPI 2)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Regadenoson After Peak Exercise</title>
            <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
          </group>
          <group group_id="O2">
            <title>Regadenoson Alone</title>
            <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Assessment of Image Quality</title>
          <description>The image quality for each scan was rated by each independent reader as 1 = Poor, 2 = Fair, 3 = Good, 4 = Excellent. Based on the median rating of overall image quality across the three readers, the number of participants with each rating is reported for each scan.</description>
          <population>Full Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="538"/>
                <count group_id="O2" value="535"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rest MPI: Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rest MPI: Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="307"/>
                    <measurement group_id="O2" value="308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rest MPI: Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rest MPI: Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stress MPI 1: Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="224"/>
                    <measurement group_id="O2" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stress MPI 1: Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="287"/>
                    <measurement group_id="O2" value="291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stress MPI 1: Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stress MPI 1: Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stress MPI 2: Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192"/>
                    <measurement group_id="O2" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stress MPI 2: Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="303"/>
                    <measurement group_id="O2" value="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stress MPI 2: Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stress MPI 2: Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target to Background Radiotracer Uptake Ratios From the First and Second Stress Scans</title>
        <description>Image quality was assessed through radiotracer uptake in the heart (target organ) compared to liver, gut and combined liver plus gut (background interference).</description>
        <time_frame>Day 1 (stress MPI 1) and Day 2 - 15 (stress MPI 2)</time_frame>
        <population>Full analysis set participants who have planar images available for each scan</population>
        <group_list>
          <group group_id="O1">
            <title>Regadenoson After Peak Exercise: MPI 1</title>
            <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
          </group>
          <group group_id="O2">
            <title>Regadenoson After Peak Exercise: MPI 2</title>
            <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
          </group>
          <group group_id="O3">
            <title>Regadenoson Alone: MPI 1</title>
            <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
          </group>
          <group group_id="O4">
            <title>Regadenoson Alone: MPI 2</title>
            <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Target to Background Radiotracer Uptake Ratios From the First and Second Stress Scans</title>
          <description>Image quality was assessed through radiotracer uptake in the heart (target organ) compared to liver, gut and combined liver plus gut (background interference).</description>
          <population>Full analysis set participants who have planar images available for each scan</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="514"/>
                <count group_id="O2" value="525"/>
                <count group_id="O3" value="518"/>
                <count group_id="O4" value="523"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Heart-to-Liver</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="0.399"/>
                    <measurement group_id="O2" value="0.94" spread="0.373"/>
                    <measurement group_id="O3" value="0.96" spread="0.365"/>
                    <measurement group_id="O4" value="0.95" spread="0.362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart-to-Gut</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" spread="0.436"/>
                    <measurement group_id="O2" value="0.99" spread="0.399"/>
                    <measurement group_id="O3" value="1.05" spread="0.428"/>
                    <measurement group_id="O4" value="0.99" spread="0.387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart-to-(Liver/Gut)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" spread="0.296"/>
                    <measurement group_id="O2" value="0.90" spread="0.260"/>
                    <measurement group_id="O3" value="0.94" spread="0.274"/>
                    <measurement group_id="O4" value="0.91" spread="0.259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Scans With Subdiaphragmatic Interference</title>
        <description>Each reader assessed the sub-diaphragmatic radiotracer interference with cardiac image quality using a 4-point scale of 0 = none, 1 = slight, 2 = moderate or 3 = severe for each stress SPECT MPI. The median rating across the 3 readers was used to summarize the percentage of scans with interference.</description>
        <time_frame>Day 1 (stress MPI 1) and Day 2 -15 (stress MPI 2)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Regadenoson After Peak Exercise: MPI 1</title>
            <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
          </group>
          <group group_id="O2">
            <title>Regadenoson After Peak Exercise: MPI 2</title>
            <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
          </group>
          <group group_id="O3">
            <title>Regadenoson Alone: MPI 1</title>
            <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
          </group>
          <group group_id="O4">
            <title>Regadenoson Alone: MPI 2</title>
            <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Scans With Subdiaphragmatic Interference</title>
          <description>Each reader assessed the sub-diaphragmatic radiotracer interference with cardiac image quality using a 4-point scale of 0 = none, 1 = slight, 2 = moderate or 3 = severe for each stress SPECT MPI. The median rating across the 3 readers was used to summarize the percentage of scans with interference.</description>
          <population>Full Analysis Set</population>
          <units>percentage of stress MPI scans</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="270"/>
                <count group_id="O4" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.8"/>
                    <measurement group_id="O2" value="63.7"/>
                    <measurement group_id="O3" value="68.1"/>
                    <measurement group_id="O4" value="67.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5"/>
                    <measurement group_id="O2" value="36.3"/>
                    <measurement group_id="O3" value="31.5"/>
                    <measurement group_id="O4" value="32.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.4"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity</title>
        <description>The number of cardiac segments obscured by the sub-diaphragmatic activity by group by stress SPECT MPI scan and by reader is reported.</description>
        <time_frame>Day 1 (stress MPI 1) and Day - 15 (stress MPI 2)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Regadenoson After Peak Exercise: MPI 1</title>
            <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
          </group>
          <group group_id="O2">
            <title>Regadenoson After Peak Exercise: MPI 2</title>
            <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
          </group>
          <group group_id="O3">
            <title>Regadenoson Alone: MPI 1</title>
            <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
          </group>
          <group group_id="O4">
            <title>Regadenoson Alone: MPI 2</title>
            <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity</title>
          <description>The number of cardiac segments obscured by the sub-diaphragmatic activity by group by stress SPECT MPI scan and by reader is reported.</description>
          <population>Full Analysis Set</population>
          <units>percentage of segments</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="538"/>
                <count group_id="O2" value="538"/>
                <count group_id="O3" value="535"/>
                <count group_id="O4" value="535"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Reader 1: Segment 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 1: Segment 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 1: Segment 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 1: Segment 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6"/>
                    <measurement group_id="O2" value="37.2"/>
                    <measurement group_id="O3" value="34.2"/>
                    <measurement group_id="O4" value="37.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 1: Segment 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7"/>
                    <measurement group_id="O2" value="8.4"/>
                    <measurement group_id="O3" value="7.9"/>
                    <measurement group_id="O4" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 1: Segment 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 1: Segment 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 1: Segment 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 1: Segment 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 1: Segment 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.6"/>
                    <measurement group_id="O2" value="35.5"/>
                    <measurement group_id="O3" value="32.3"/>
                    <measurement group_id="O4" value="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 1: Segment 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="8.2"/>
                    <measurement group_id="O3" value="7.5"/>
                    <measurement group_id="O4" value="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 1: Segment 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 1: Segment 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 1: Segment 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 1: Segment 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="0.9"/>
                    <measurement group_id="O3" value="2.4"/>
                    <measurement group_id="O4" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 1: Segment 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.2"/>
                    <measurement group_id="O4" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 1: Segment 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 2: Segment 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 2: Segment 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.2"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 2: Segment 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.2"/>
                    <measurement group_id="O4" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 2: Segment 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4"/>
                    <measurement group_id="O2" value="35.1"/>
                    <measurement group_id="O3" value="32.5"/>
                    <measurement group_id="O4" value="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 2: Segment 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="0.4"/>
                    <measurement group_id="O3" value="0.7"/>
                    <measurement group_id="O4" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 2: Segment 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 2: Segment 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 2: Segment 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.2"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 2: Segment 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.4"/>
                    <measurement group_id="O4" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 2: Segment 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6"/>
                    <measurement group_id="O2" value="11.9"/>
                    <measurement group_id="O3" value="13.8"/>
                    <measurement group_id="O4" value="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 2: Segment 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.2"/>
                    <measurement group_id="O3" value="0.6"/>
                    <measurement group_id="O4" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 2: Segment 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 2: Segment 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 2: Segment 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 2: Segment 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1"/>
                    <measurement group_id="O2" value="8.7"/>
                    <measurement group_id="O3" value="10.5"/>
                    <measurement group_id="O4" value="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 2: Segment 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.2"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 2: Segment 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 3: Segment 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.2"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 3: Segment 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 3: Segment 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 3: Segment 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="17.9"/>
                    <measurement group_id="O4" value="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 3: Segment 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="0.4"/>
                    <measurement group_id="O3" value="0.7"/>
                    <measurement group_id="O4" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 3: Segment 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 3: Segment 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 3: Segment 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 3: Segment 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 3: Segment 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0"/>
                    <measurement group_id="O2" value="17.8"/>
                    <measurement group_id="O3" value="18.5"/>
                    <measurement group_id="O4" value="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 3: Segment 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="0.2"/>
                    <measurement group_id="O3" value="0.6"/>
                    <measurement group_id="O4" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 3: Segment 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 3: Segment 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 3: Segment 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 3: Segment 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9"/>
                    <measurement group_id="O2" value="13.8"/>
                    <measurement group_id="O3" value="13.1"/>
                    <measurement group_id="O4" value="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 3: Segment 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="0.4"/>
                    <measurement group_id="O4" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reader 3: Segment 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="0.9"/>
                    <measurement group_id="O3" value="0.7"/>
                    <measurement group_id="O4" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events Within 24 Hours After Administration of Regadenoson</title>
        <description>An adverse event is considered “serious” if, in the view of either the investigator or sponsor, it results in any of the following outcomes:
Results in death,
Is life threatening,
Results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions,
Results in congenital anomaly, or birth defect,
Requires inpatient hospitalization or leads to prolongation of hospitalization
Other medically important events.
Relationship to study drug was assessed by the investigator.</description>
        <time_frame>Up to 24 hours after study drug administration for each stress MPI (Day 1 and Day 2-15)</time_frame>
        <population>Safety Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Regadenoson After Peak Exercise: MPI 1</title>
            <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
          </group>
          <group group_id="O2">
            <title>Regadenoson After Peak Exercise: MPI 2</title>
            <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
          </group>
          <group group_id="O3">
            <title>Regadenoson Alone: MPI 1</title>
            <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
          </group>
          <group group_id="O4">
            <title>Regadenoson Alone: MPI 2</title>
            <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events Within 24 Hours After Administration of Regadenoson</title>
          <description>An adverse event is considered “serious” if, in the view of either the investigator or sponsor, it results in any of the following outcomes:
Results in death,
Is life threatening,
Results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions,
Results in congenital anomaly, or birth defect,
Requires inpatient hospitalization or leads to prolongation of hospitalization
Other medically important events.
Relationship to study drug was assessed by the investigator.</description>
          <population>Safety Analysis Set.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="575"/>
                <count group_id="O2" value="544"/>
                <count group_id="O3" value="567"/>
                <count group_id="O4" value="548"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302"/>
                    <measurement group_id="O2" value="317"/>
                    <measurement group_id="O3" value="329"/>
                    <measurement group_id="O4" value="323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291"/>
                    <measurement group_id="O2" value="298"/>
                    <measurement group_id="O3" value="319"/>
                    <measurement group_id="O4" value="308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse events leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related AEs leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Regadenoson After Peak Exercise: MPI 1</title>
          <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
        </group>
        <group group_id="E2">
          <title>Regadenoson After Peak Exercise: MPI 2</title>
          <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
        </group>
        <group group_id="E3">
          <title>Regadenoson Alone: MPI 1</title>
          <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
        </group>
        <group group_id="E4">
          <title>Regadenoson Alone: MPI 2</title>
          <description>On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="575"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="544"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="567"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="548"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="567"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="567"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="567"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="544"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="567"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="548"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="567"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="548"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="544"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="567"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="548"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Anticoagulation drug level below therapeutic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="567"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="567"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="548"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="567"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="567"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="567"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="548"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="277" subjects_at_risk="575"/>
                <counts group_id="E2" subjects_affected="274" subjects_at_risk="544"/>
                <counts group_id="E3" subjects_affected="307" subjects_at_risk="567"/>
                <counts group_id="E4" subjects_affected="290" subjects_at_risk="548"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="575"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="544"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="567"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="575"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="544"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="567"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="548"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="575"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="544"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="567"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="548"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="575"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="544"/>
                <counts group_id="E3" subjects_affected="89" subjects_at_risk="567"/>
                <counts group_id="E4" subjects_affected="81" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="575"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="544"/>
                <counts group_id="E3" subjects_affected="137" subjects_at_risk="567"/>
                <counts group_id="E4" subjects_affected="118" subjects_at_risk="548"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="575"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="544"/>
                <counts group_id="E3" subjects_affected="161" subjects_at_risk="567"/>
                <counts group_id="E4" subjects_affected="152" subjects_at_risk="548"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="575"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="544"/>
                <counts group_id="E3" subjects_affected="79" subjects_at_risk="567"/>
                <counts group_id="E4" subjects_affected="69" subjects_at_risk="548"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data or 18 months after data-lock, whichever is first. Sponsor must receive a site’s manuscript at least 45 days prior to publication for review and comment. Sponsor may delay the publication for up to 60 days to seek patent protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Medical Director, Medical Affairs</name_or_title>
      <organization>Astellas Pharma Global Development, Inc. (APGD)</organization>
      <email>Astellas.resultsdisclosure@astellas.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

